Peisheng Hu, PhD

Research Assistant Professor of Pathology (Part-Time)

Image of Peisheng Hu, PhD
Is this your profile? Click to edit


  • Brain Disposition of Antibody-Based Therapeutics: Dogma, Approaches and Perspectives Int J Mol Sci. 2021 Jun 16; 22(12). . View in PubMed
  • Spatio-temporal biodistribution of 89Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model Sci Rep. 2021 07 23; 11(1):15077. . View in PubMed
  • Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations Antibodies (Basel). 2020 Jun 10; 9(2). . View in PubMed
  • A Humanized Lym-1 CAR with Novel DAP10/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma Models Clin Cancer Res. 2020 07 15; 26(14):3694-3706. . View in PubMed
  • Costimulation of type-2 innate lymphoid cells by GITR promotes effector function and ameliorates type 2 diabetes Nat Commun. 2019 02 12; 10(1):713. . View in PubMed
  • Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma Int J Mol Sci. 2017 Dec 20; 18(12). . View in PubMed
  • Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models Cancer Immunol Immunother. 2016 May; 65(5):511-23. . View in PubMed
  • Phase 1 Dose-Escalation Study with LEC/chTNT-3 and Toceranib Phosphate (Palladia®) in Dogs with Spontaneous Malignancies J Cancer Sci Ther. 2015; 7(6):167-174. . View in PubMed
  • A hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibody ACS Nano. 2014 Mar 25; 8(3):2064-76. . View in PubMed
  • Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy J Immunother. 2013 Nov-Dec; 36(9):477-89. . View in PubMed
  • Generation of tumor-targeted antibody-CpG conjugates J Immunol Methods. 2013 Mar 29; 389(1-2):45-51. . View in PubMed
  • Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models J Immunother. 2008 Apr; 31(3):235-45. . View in PubMed
  • Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer Clin Cancer Res. 2008 Jan 15; 14(2):579-88. . View in PubMed
  • Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy Clin Cancer Res. 2007 Jul 01; 13(13):4016-25. . View in PubMed
  • Lym-1-induced apoptosis of non-Hodgkin’s lymphomas produces regression of transplanted tumors Cancer Biother Radiopharm. 2007 Jun; 22(3):342-56. . View in PubMed
  • RA8, a human anti-CD25 antibody against human Treg cells Hybridoma (Larchmt). 2007 Jun; 26(3):119-30. . View in PubMed
  • Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors Clin Cancer Res. 2007 May 01; 13(9):2758-67. . View in PubMed
  • Soluble Fc fusion proteins for biomedical research Methods Mol Biol. 2007; 378:33-52. . View in PubMed
  • B71/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors. J Immunother. 2006 Jul-Aug; 29(4):425-35. . View in PubMed
  • H60/TNT-3 fusion protein activates NK cells in vitro and improves immunotherapeutic outcome in murine syngeneic tumor models J Immunother. 2006 May-Jun; 29(3):274-83. . View in PubMed
  • Combination B7-Fc fusion protein treatment and Treg cell depletion therapy Clin Cancer Res. 2005 Dec 01; 11(23):8492-502. . View in PubMed
  • Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin’s lymphomas Clin Cancer Res. 2005 Aug 15; 11(16):5971-80. . View in PubMed
  • NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy Clin Cancer Res. 2005 Apr 15; 11(8):3084-93. . View in PubMed
  • chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumors Hybrid Hybridomics. 2004 Feb; 23(1):1-10. . View in PubMed
  • Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion Cancer Res. 2003 Dec 01; 63(23):8384-92. . View in PubMed
  • Tumor targeting properties of indium-111 labeled genetically engineered Fab’ and F(ab’)2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody Cancer Biother Radiopharm. 2003 Dec; 18(6):931-40. . View in PubMed
  • Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis Cancer Res. 2003 Aug 15; 63(16):5046-53. . View in PubMed
  • Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies Hybrid Hybridomics. 2003 Aug; 22(4):197-207. . View in PubMed
  • LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors J Immunother. 2003 Jul-Aug; 26(4):320-31. . View in PubMed
  • Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity Blood. 2003 Jun 15; 101(12):4853-61. . View in PubMed
  • Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT) Cancer Biother Radiopharm. 2003 Jun; 18(3):339-53. . View in PubMed
  • Identification of a protein fragment of interleukin 2 responsible for vasopermeability J Natl Cancer Inst. 2003 May 21; 95(10):741-9. . View in PubMed
  • Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors Hybrid Hybridomics. 2003 Feb; 22(1):1-9. . View in PubMed
  • Generation of human interferon gamma and tumor Necrosis factor alpha chimeric TNT-3 fusion proteins Hybrid Hybridomics. 2002 Dec; 21(6):421-32. . View in PubMed
  • Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin Cancer Biother Radiopharm. 2002 Aug; 17(4):359-70. . View in PubMed
  • Stable, genetically engineered F(ab’)(2) fragments of chimeric TNT-3 expressed in mammalian cells Hybrid Hybridomics. 2002 Feb; 21(1):11-8. . View in PubMed